TrialDiabetes, obesity & metabolism2022

Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.

Jianping Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.